35% Of Those With Alzheimer’s Using FDA-Approved Drug Aducanumab Had Brain Swelling

Approximately 35.2% of those diagnosed with Alzheimer's disease and are using aducanumab had ARIA-edema (ARIA-E, or brain swelling). About 72.7% of these brain swelling events happened within the first eight doses of aducanumab. Aducanumab is a prescription-only amyloid beta-directed antibody indicated to treat Alzheimer’s disease that is approved by the U.S. Food and Drug Administration (FDA).

This researchers did not indicate whether the ARIA statistics were "good" or "bad" in this determination of radiographic and clinical characteristics of ARIA in those with Alzheimer's who were given aducanumab. However they do . . .